Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA will meet user fee goals

Executive Summary

Shortly after Office of New Drugs Director John Jenkins granted CDER staff permission to miss PDUFA goals, Commissioner Andrew von Eschenbach reaffirmed FDA's commitment to the user fee program. "We intend to live up to the commitments that are outlined in those user fee programs. They will be difficult to adhere to because of the complexities of bringing personnel into the agency," he said at the FDLI conference March 26 (1"The Pink Sheet," March 17, 2008, p. 11). However, "we have a very detailed and month-by-month program with targets and methods of acquisition across the various centers, and ... we have approximately met about one-quarter to one-third of [the] target at this point.

You may also be interested in...



FDA Misses User Fee Goals As Resources Tighten For Application Reviews, SPAs

With the ink of the reauthorized Prescription Drug User Fee Act still drying, FDA is signaling that it may be some time before the agency will consistently meet the performance goals of its user fee program

P&G's $8M Benzene Settlement Preliminarily Approved By Ohio Federal Court

The Cincinnati, OH-based firm will pay $8m to recompense Unites States residents who purchased aerosol personal-care products potentially contaminated with benzene over a roughly six-year period.

Food For Thought On US FDA Reforms

An independent review of the US FDA’s food regulatory programs could renew a debate over splitting FDA into two agencies. That could be a distraction for the agency in the coming year – but it could also help keep the medical product review groups out of the political hot seat.

Latest News
See All
UsernamePublicRestriction

Register

PS049458

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel